876372-92-8

Upstream product

• 766-11-0 5-bromo-2-fluoropyridine 
• 77992-44-0 5-bromo-2-hydrazinylpyridine 
• 7377-26-6 4-Methoxycarbonylbenzoyl chloride 

Downstream Products

• 876372-96-2 methyl 4-[6-(2,4-difluorobenzyl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]benzoate 

Relevant academic research and scientific papers

CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION

Compounds of Formula I, Formula II, and Formula III and the pharmaceutically acceptable salts thereof are disclosed. The variables X, a, b, c, d, R1-4, R10-15 and R17-22 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving M2 phenotype of macrophages. Pharmaceutical compositions containing compounds of Formula I or Formula II or Formula III and methods of treatment comprising administering compounds of Formula I and Formula II and Formula III are also disclosed.

NOVEL TRIAZOLOPYRIDINE COMPOUNDS

This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula (I): wherein R

NOVEL TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION

This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula (I): Wherein R1, R2, R3, R4, and R5are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.